Oppenheimer expects Verastem to make continued progress on its cancer treatment, providing increasing validation for its platform. The firm thinks the company will ultimately make a strategic deal, and it views the stock as a compelling long-term investment. Oppenheimer maintains a $16 price target and Outperform rating on the stock.
- Mergers, Acquisitions & Takeovers
- Investment & Company Information